Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

age number of shares outstanding of 1,305.2 million in the first quarter of 2011 and 1,307.3 in the  first quarter of 2010.Appendix 9: Definitions Re-presentation of Merial resultsIn accordance with IFRS 5.36 and as Merial has ceased to be qualified as held for sale or exchange in Q1/2011, the results of Merial classified as held for sale or exchange in previously-issued financial statements have been reclassified and included in income from continuing operations for all periods presented.

Definitions of non-GAAP financial indicatorsNet sales at constant exchange rates

When we refer to changes in our net sales "at constant exchange rates," this means that we exclude the effect of changes in exchange rates.

We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for the previous period.

Reconciliation of reported net sales to net sales at constant exchange rates for the first quarter of 2011(millions of euros)Q1 2011Net sales

7,779Effect of exchange rates

(289)Net sales at constant exchange rates

7,490Net sales on a constant structure basis

We eliminate the effect of changes in structure by restating prior-period net sales as follows:

  • by including sales from the acquired entity or product rights for a portion of the prior period equal to the portion of the current period during which we owned them, based on sales information we receive from the party from whom we make the acquisition;
  • similarly, by excluding sales in the relevant portion of the prior period when we have sold an entity or rights to a product;
  • for a change in consolidation method, by recalculating the prior period on the basis of the method used for the current period.

  • Worldwide presence of Plavix®/Iscover®, Avapro®/Aprovel®

    When we refer to the "worldwide presence" of a product, we mean our consolida
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

    Related medicine technology :

    1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
    6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
    7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
    8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
    9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
    10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
    11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... , July 24, 2014  Perrigo Company (NYSE: ... has received an AB therapeutic equivalent rating from the ... approved New Drug Application (NDA) for testosterone gel 1.0%. ... to [AbbVie,s] AndroGel 1% and can be substituted with ... clinical effect and safety profile as AndroGel 1% when ...
    (Date:7/24/2014)... DUBLIN , July 24, 2014 ... "Machine Health Monitoring Market by Product, Component, Application ... report to their offering. ... monitoring market is expected to witness a moderate growth ... Europe have almost reached the saturation levels. ...
    (Date:7/24/2014)... /PRNewswire-iReach/ -- Delivery of the Report will take ... Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... survey on Global and Chinese Hemodialysis Machine industry. ... Hemodialysis Machine including its classification, application and manufacturing ... top manufacturers of Hemodialysis Machine listing their product ...
    Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5
    ... PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - ... 2 clinical,trial results for Hematide(TM) were presented ... in Barcelona, Spain by Iain C.,Macdougall, M.D., ... Macdougall's poster included data in previously-treated,dialysis patients ...
    ... also Showed Sustained Improvements in Blood Glucose,Control ... 23, 2007 /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. and ... a study that showed BYETTA(R) (exenatide) injection,sustained ... weight,loss through three and a half years ...
    Cached Medicine Technology:Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 2Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6
    (Date:7/24/2014)... off nighttime production of the hormone melatonin, renders breast ... cancer drug, says a new study by Tulane University ... Melatonin Disruption by Exposure to Light at Night Drives ... in the journal Cancer Research , is the ... success of tamoxifen in treating breast cancer. , , ...
    (Date:7/24/2014)... The report, “Content Delivery Networks (CDN) ... various sub-segments with an in-depth analysis and forecasting ... restraints for this market with insights on trends, ... tables and 36 figures spread through 157 pages ... Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early ...
    (Date:7/24/2014)... Amy Norton HealthDay Reporter THURSDAY, ... teenage boy may be dead wrong, according to a small study ... In interviews with 33 boys between the ages of 14 and ... a girl for the closeness and trust. Very few boasted about ... a relationship with a girl. "In our culture, we have ...
    (Date:7/24/2014)... Pools and beaches are the place to be ... especially for small children, so Amica Insurance is ... the Centers for Disease Control and Prevention, children between the ... water-related injuries and deaths. It’s important to know the best ... is offering the following tips from the American Red Cross:, ...
    (Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- Drinking caffeine ... affect roughly two-thirds of women as they go through ... are preliminary, our study suggests that limiting caffeine intake ... bothersome hot flashes and night sweats," said researcher Dr. ... the Mayo Clinic in Rochester, Minn. But caffeine ...
    Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Is Coffee Aggravating Your Hot Flashes? 2
    ... Inc. (Nasdaq and SWX: BMRN) today announced that,Jean-Jacques ... a,conference call and webcast on Tuesday, February 26, ... quarter and full year 2007 financial results., ... International Dial-in Number: 617.597.5312 Participant ...
    ... Present at Merrill Lynch,s Global Pharmaceutical Conference Feb. ... ... today that it will host a conference call and live webcast on,Wednesday, Feb. ... nine months ended Dec. 31, 2007. The Company also will provide,an operational and ...
    ... Mrs. Bojan M. Kuure, of,Jakobstad, Finland, has ... for her outstanding contributions and achievements in the,field ... About Mrs. Bojan M. Kuure, Mrs. ... a dedicated registered,nurse. She obtained a Special Registered ...
    ... Feb. 5 Watson,Pharmaceuticals, Inc. (NYSE: WPI ... the company expects to initiate shipments of,alendronate sodium ... dosage strengths when,Fosamax(R) loses market exclusivity, which is ... February 6, 2008. Alendronate sodium is the generic,version ...
    ... Feb. 5 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical ... cancer, announced today that it will,host a conference ... Time on,Tuesday, February 19, 2008 to discuss the ... A press release will be issued before the ...
    ... Youth may be more,likely victimized while using instant messenger ... new research this week reports., The study, conducted ... Kids and Kimberly Mitchell of the University of New,Hampshire, ... youth are most likely,to experience sexual solicitation and harassment. ...
    Cached Medicine News:Health News:BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET) 2Health News:Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007 2Health News:Bojan M. Kuure Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Watson to Distribute Alendronate Tablets 2Health News:Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008 2Health News:Are Social Networking Sites Endangering Young Teens? Study Finds Maybe Not 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: